Quick Take
Retatrutide is the next evolution — a TRIPLE agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24% weight loss, beating even tirzepatide. Even more exciting: emerging data suggests potential anti-cancer properties.
How It Works
Simple Explanation
Retatrutide activates THREE receptors: GLP-1 and GIP (like tirzepatide) PLUS glucagon. The glucagon component adds extra fat-burning and may help preserve muscle during weight loss.
🔬 Technical Details (Click to expand)
Triple agonism of GLP-1/GIP/glucagon receptors provides appetite suppression, improved glucose handling, AND increased energy expenditure via glucagon's thermogenic effects. The glucagon component may also reduce liver fat and improve lipid profiles.
Key Research
Benefits
- Highest weight loss seen in trials (24%+)
- May preserve muscle better than other options
- Significant liver fat reduction
- Potential anti-cancer properties (under investigation)
- Triple mechanism may mean better outcomes
Side Effects
- Nausea — CommonSimilar to other GLP-1s
- Diarrhea — Common
- Vomiting — Common
- Decreased appetite — Very common
Typical Dosing
Standard Dose
Phase 3 testing doses up to 12mg weekly
Forms Available
- • Subcutaneous injection
Frequency
Once weekly
⚠️ This is general information only. Always consult a healthcare provider before starting any peptide.
Who It's For
- ✓ Those wanting cutting-edge weight loss
- ✓ People interested in research compounds
- ✓ Those who want maximum efficacy
- ✓ Biohackers willing to accept research-stage risks
Who Should Avoid
- ✗ Anyone needing FDA-approved medications
- ✗ Risk-averse individuals
- ✗ Pregnant or planning pregnancy
- ✗ Those uncomfortable with research chemicals
Want the Full Protocol Guide?
Get our comprehensive guide with dosing protocols, stacking strategies, and more.